
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ALFRY and 80,000+ other tickers.
See exactly how ALFRY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ALFRY and 80,000+ other tickers.
Tokyo, Japan-based Alfresa Holdings Corporation, established in 2003, is a diversified entity operating domestically and internationally within the healthcare industry. The company's core activities encompass the production, wholesale distribution, marketing, and global trade of pharmaceuticals, diagnostic agents, and medical equipment. Alfresa operates through distinct wholesale divisions, including an ethical pharmaceuticals segment that supplies hospitals, clinics, and pharmacies with essential diagnostic reagents, medical devices, and prescription drugs. Another division specializes in…
No recent news available.